Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.

Literature DB >> 11825538

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.

Markus Cornberg¹, Heiner Wedemeyer, Michael P Manns.

Abstract

Treatment with interferon alfa combined with ribavirin is successful in approximately 40% to 45% of patients with chronic hepatitis C viral infection (HCV). However, response rates are disappointing in patients who are difficult to treat, such as those infected with HCV genotype 1, high viral load, or advanced liver fibrosis. In addition, low tolerability and significant side effects of therapy frequently lead to dose reduction and treatment discontinuation, decreasing response rates further. Thus, investigation of new treatment options and innovations for chronic HCV infection are vital. This review describes recent advances in the treatment of HCV infection with PEGylated interferon (interferon modified with polyethylene glycol [PEG] ) combined with ribavirin.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2002 PMID： 11825538 DOI： 10.1007/s11894-002-0034-y

Source DB: PubMed Journal: Curr Gastroenterol Rep ISSN： 1522-8037

24 in total

1. Paroxetine for the prevention of depression induced by high-dose interferon alfa.

Authors: D L Musselman; D H Lawson; J F Gumnick; A K Manatunga; S Penna; R S Goodkin; K Greiner; C B Nemeroff; A H Miller
Journal: N Engl J Med Date: 2001-03-29 Impact factor: 91.245

2. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.

Authors: N P Lam; A U Neumann; D R Gretch; T E Wiley; A S Perelson; T J Layden
Journal: Hepatology Date: 1997-07 Impact factor: 17.425

3. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

Authors: P Bailon; A Palleroni; C A Schaffer; C L Spence; W J Fung; J E Porter; G K Ehrlich; W Pan; Z X Xu; M W Modi; A Farid; W Berthold; M Graves
Journal: Bioconjug Chem Date: 2001 Mar-Apr Impact factor: 4.774

4. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.

Authors: M L Shiffman; C M Hofmann; M J Contos; V A Luketic; A J Sanyal; R K Sterling; A Ferreira-Gonzalez; A S Mills; C Garret
Journal: Gastroenterology Date: 1999-11 Impact factor: 22.682

5. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection.

Authors: S Barrett; J Goh; B Coughlan; E Ryan; S Stewart; A Cockram; J C O'Keane; J Crowe
Journal: Gut Date: 2001-09 Impact factor: 23.059

6. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal: Lancet Date: 2001-09-22 Impact factor: 79.321

7. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors: T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal: Lancet Date: 1998-10-31 Impact factor: 79.321

8. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

Authors: R Sobesky; P Mathurin; F Charlotte; J Moussalli; M Olivi; M Vidaud; V Ratziu; P Opolon; T Poynard
Journal: Gastroenterology Date: 1999-02 Impact factor: 22.682

9. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors: J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal: N Engl J Med Date: 1998-11-19 Impact factor: 91.245

10. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors: S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal: Lancet Date: 1995-10-21 Impact factor: 79.321

19 in total

1. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).

Authors: Kenneth E Sherman; Janet W Andersen; Adeel A Butt; Triin Umbleja; Beverly Alston; Margaret J Koziel; Marion G Peters; Mark Sulkowski; Zachary D Goodman; Raymond T Chung
Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731

2. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.

Authors: Th Witthoeft; M Fuchs; D Ludwig
Journal: World J Gastroenterol Date: 2007-01-28 Impact factor: 5.742

3. Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection.

Authors: Naoki Mori; Kazunori Nakasone; Koh Tomimori; Chie Ishikawa
Journal: World J Gastroenterol Date: 2012-05-14 Impact factor: 5.742

Review 4. Treating viral hepatitis C: efficacy, side effects, and complications.

Authors: M P Manns; H Wedemeyer; M Cornberg
Journal: Gut Date: 2006-09 Impact factor: 23.059

5. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Authors: Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried
Journal: J Clin Pharmacol Date: 2009-10-19 Impact factor: 3.126